Adam Brufsky

Also affiliated with Magee-Womens Hospital, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile

0.742Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

medRxiv(2023)10.1101/2023.03.06.23286772

Top 27%

0.742DataRank

Top 27%12 citations

Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong +24 more

Papers

Driven by 29 papers — median percentile 73. Top paper: “Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial”.

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

Annals of Oncology(2020)10.1016/j.annonc.2020.05.012

N/A

3.1DataRank · unranked

106 citations

Sara A. Hurvitz, Jack A. Di Palma, Ron Bose, A. Jo Chien, Nicholas Iannotti +48 more

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

Annals of Oncology(2023)10.1016/j.annonc.2023.08.004

N/A

1.7DataRank · unranked

58 citations

Timothy Blewett, Xun Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong +24 more

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

Annals of Oncology(2023)10.1016/j.annonc.2023.08.003

N/A

1.4DataRank · unranked

61 citations

L.D. Eli, Hans Wildiers, Sara A. Hurvitz, Ángel Guerrero‐Zotano, Nisha Unni +37 more

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

medRxiv(2023)10.1101/2023.03.06.23286772

Top 27%

0.742DataRank

Top 27%12 citations

Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong +24 more

Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

Breast Cancer Research and Treatment(2022)10.1007/s10549-021-06417-y

N/A

0.593DataRank · unranked

10 citations

Hanna Bandos, Priya Rastogi, Samuel A. Jacobs, André Robidoux, Louis Fehrenbacher +13 more

Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-5017

N/A

0.538DataRank · unranked

35 citations

Christine I. Rafie, Chenguang Wang, David Lim, Adam Brufsky, Patricia LoRusso +16 more

Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.501

N/A

0DataRank · unranked

22 citations

Hanna Bandos, Priya Rastogi, Yi Zhang, Kai Treuner, Peter C. Lucas +14 more

Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.502

N/A

0DataRank · unranked

16 citations

Hanna Bandos, Peter C. Lucas, L. J. van ‘t Veer, Jia-Perng Jennifer Wei, Charles E. Geyer +15 more

Definitive Results of a Phase III Adjuvant Trial Comparing Six Cycles of FEC-100 to Four Cycles of AC in Women with Operable Node-negative Breast Cancer: The NSABP B-36 Trial (NRG Oncology)

Research Square(2021)10.21203/rs.3.rs-841103/v1

N/A

0DataRank · unranked

3 citations

Hanna Bandos, Priya Rastogi, Samuel A. Jacobs, André Robidoux, Louis Fehrenbacher +13 more

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Annals of Oncology(2022)10.1016/j.annonc.2022.09.159

N/A

0DataRank · unranked

450 citations

Judy E. Garber, Richard D. Gelber, Greg Yothers, Manuel Taboada, L. Ross +93 more

A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013

npj Breast Cancer(2022)10.1038/s41523-022-00500-3

N/A

0DataRank · unranked

54 citations

Feng Gao, Cherease R. Street, Ina Chen, Donald W. Northfelt, Robert Wesolowski +21 more

Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers

npj Breast Cancer(2022)10.1038/s41523-022-00415-z

N/A

0DataRank · unranked

27 citations

Tiannan Wang, Beth Z. Clark, Jing Yu, Jeffrey L. Fine, Tatiana Villatoro +10 more

“I was never one of those people who just jumped right in for me”: Patient perspectives on self-advocacy training for women with advanced cancer

Research Square(2022)10.21203/rs.3.rs-1468295/v1

N/A

0DataRank · unranked

1 citations

Patty Jo Murray, Margaret Rosenzweig, Sarah Taylor, Adam Brufsky, Catherine M. Bender +3 more

Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad078

N/A

0DataRank · unranked

20 citations

Hanna Bandos, Priya Rastogi, Barry C. Lembersky, Jong‐Hyeon Jeong, Charles E. Geyer +11 more

A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression

JCO Precision Oncology(2023)10.1200/po.22.00532

N/A

0DataRank · unranked

16 citations

Taronish D. Dubash, Gabriela N. Johnson, Andrzej Niemierko, Veronica Mariotti, Leslie S.L. Kim +27 more

The feasibility, acceptability, and preliminary efficacy of a self‐advocacy serious game for women with advanced breast or gynecologic cancer

Cancer(2023)10.1002/cncr.34887

N/A

0DataRank · unranked

12 citations

Catherine M. Bender, Heidi Donovan, Patty Jo Murray, Sarah E. Taylor, Margaret Rosenzweig +4 more

“I was never one of those people who just jumped right in for me”: patient perspectives on self-advocacy training for women with advanced cancer

Supportive Care in Cancer(2023)10.1007/s00520-022-07531-3

N/A

0DataRank · unranked

9 citations

Patty Jo Murray, Margaret Rosenzweig, Sarah E. Taylor, Adam Brufsky, Catherine M. Bender +3 more

Omission of surgery, primary endocrine therapy adherence, and effect of comorbidity in older women with estrogen receptor positive breast cancer

Journal of Geriatric Oncology(2023)10.1016/j.jgo.2023.101679

N/A

0DataRank · unranked

4 citations

Hira Abidi, Susrutha Puthanmadhomnarayanan, Oscar C. Marroquin, Steffi Oesterreich, Emilia J. Diego +4 more

Racial disparity in dose intensity of early-stage breast cancer chemotherapy.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.6556

N/A

0DataRank · unranked

0 citations

Susan R. Mazanec, Adam Brufsky, Brittaney-Belle Elizabeth Gordon, Margaret Rosenzweig

Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial

Nature Cancer(2024)10.1038/s43018-024-00729-w

N/A

0DataRank · unranked

47 citations

Won Jin Ho, Ludmila Danilova, Joseph A. Tandurella, James M. Leatherman, Christine I. Rafie +22 more

Association of early menarche with breast tumor molecular features and recurrence

Breast Cancer Research(2024)10.1186/s13058-024-01839-0

N/A

0DataRank · unranked

20 citations

Tengteng Wang, Yujing J. Heng, Gabrielle M. Baker, Phuong Anh Le, Jun Wang +12 more

Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues

UNC Libraries(2024)10.17615/y88b-pw80

N/A

0DataRank · unranked

0 citations

David J. Hunter, A. Heather Eliassen, RM Tamimi, Xiang Zhang, Christine B. Ambrosone +15 more

Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa148

N/A

0DataRank · unranked

115 citations

Robert J. Gray, Della Makower, Amir Faghih, Daniel F. Hayes, Charles E. Geyer +23 more

Hope for OTHERS (Our Tissue Helping Enhance Research & Science): research results from the University of Pittsburgh rapid autopsy program for breast cancer

Breast Cancer Research(2025)10.1186/s13058-025-02014-9

N/A

0DataRank · unranked

4 citations

Marija Balić, Tanner Bartholow, Rohit Bhargava, Daniel D. Brown, Lauren Brown +34 more

The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network

Cancer Epidemiology Biomarkers & Prevention(2020)10.1158/1055-9965.epi-19-1087

N/A

0DataRank · unranked

14 citations

Susan E. Hankinson, Jun Wang, Ludmil B. Alexandrov, Christine B. Ambrosone, Victor Piana de Andrade +9 more

Leveraging Bayesian networks and information theory to learn risk factors for breast cancer metastasis

BMC Bioinformatics(2020)10.1186/s12859-020-03638-8

N/A

0DataRank · unranked

13 citations

Alan Wells, Adam Brufsky, Darshan Shetty, Kahmil Shajihan, Richard E. Neapolitan +1 more

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

Digital Commons@Becker (Washington University School of Medicine)(2020)10.17615/6e7v-pv95

N/A

0DataRank · unranked

1 citations

Tracy Lively, John A. Olson, Robert J. Gray, Virginia Kaklamani, Della Makower +26 more

Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps1102

N/A

0DataRank · unranked

10 citations

Mary Josephine Paula Pilat, Cesar Augusto Santa-Maria, Roisín M. Connolly, Erin Roesch, Anosheh Afghahi +15 more

Assisting decision making on the use of carboplatin for metastatic breast cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e13008

N/A

0DataRank · unranked

0 citations

Margaret Rosenzweig, Adam Brufsky, Juan Luis Gomez Marti

Adam Brufsky

Indexed papers

Top data-sharing exemplar

Papers